A SNP in the HTT promoter alters NF-κB binding and is a bidirectional genetic modifier of Huntington disease

[1]  L. Kruglyak,et al.  The role of regulatory variation in complex traits and disease , 2015, Nature Reviews Genetics.

[2]  Xihong Lin,et al.  Detecting Rare Variant Effects Using Extreme Phenotype Sampling in Sequencing Association Studies , 2013, Genetic epidemiology.

[3]  Jing Liu,et al.  Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin Expression , 2012, Cell.

[4]  M. Rieder,et al.  Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis , 2012, Nature Genetics.

[5]  Weihui Zhou,et al.  Sp1 Regulates Human Huntingtin Gene Expression , 2012, Journal of Molecular Neuroscience.

[6]  S. Freier,et al.  Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  J. Ott,et al.  Family-based designs for genome-wide association studies , 2011, Nature Reviews Genetics.

[8]  D. Sah,et al.  Oligonucleotide therapeutic approaches for Huntington disease. , 2011, The Journal of clinical investigation.

[9]  C. Ross,et al.  Huntington's disease: from molecular pathogenesis to clinical treatment , 2011, The Lancet Neurology.

[10]  L. Tong,et al.  Age at onset in Huntington’s disease is modified by the autophagy pathway: implication of the V471A polymorphism in Atg7 , 2010, Human Genetics.

[11]  V. Salomaa,et al.  Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia , 2010, Nature Genetics.

[12]  M. Gerstein,et al.  Variation in Transcription Factor Binding Among Humans , 2010, Science.

[13]  Sailu Yellaboina,et al.  Comparing Transcription Rate and mRNA Abundance as Parameters for Biochemical Pathway and Network Analysis , 2010, PloS one.

[14]  Jane S. Paulsen,et al.  CAG‐repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[15]  Mathieu Blanchette,et al.  Global patterns of cis variation in human cells revealed by high-density allelic expression analysis , 2009, Nature Genetics.

[16]  M. MacDonald,et al.  Huntington's disease: the case for genetic modifiers , 2009, Genome Medicine.

[17]  I. Martins,et al.  Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  E. Budtz-Jørgensen,et al.  4p16.3 haplotype modifying age at onset of Huntington disease , 2009, Clinical genetics.

[19]  G. Bonvento,et al.  Sustained effects of nonallele‐specific Huntingtin silencing , 2009, Annals of neurology.

[20]  B. Landwehrmeyer,et al.  The gene coding for PGC-1α modifies age at onset in Huntington's Disease , 2009, Molecular Neurodegeneration.

[21]  R. Friedlander,et al.  Allele‐specific silencing of mutant Huntington’s disease gene , 2009, Journal of neurochemistry.

[22]  E. Génin,et al.  Identifying modifier genes of monogenic disease: strategies and difficulties , 2008, Human Genetics.

[23]  A. Rego,et al.  Mechanisms of neurodegeneration in Huntington’s disease , 2008, European Journal of Neuroscience.

[24]  L. Tong,et al.  Huntingtin-associated protein-1 is a modifier of the age-at-onset of Huntington's disease. , 2008, Human molecular genetics.

[25]  David J. Arenillas,et al.  In Silico Detection of Sequence Variations Modifying Transcriptional Regulation , 2007, PLoS Comput. Biol..

[26]  K. G. Rajeev,et al.  Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits , 2007, Proceedings of the National Academy of Sciences.

[27]  M. Hayden,et al.  Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease , 2006, BMC Neuroscience.

[28]  M. Hayden,et al.  Body weight is modulated by levels of full-length huntingtin. , 2006, Human molecular genetics.

[29]  M. Hayden,et al.  Wild‐type huntingtin protects neurons from excitotoxicity , 2006, Journal of neurochemistry.

[30]  L. Raymond,et al.  Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models , 2006, Neurobiology of Disease.

[31]  A. Levine,et al.  p53 tumor suppressor protein regulates the levels of huntingtin gene expression , 2006, Oncogene.

[32]  M. Hayden,et al.  Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. , 2005, Human molecular genetics.

[33]  H. Paulson,et al.  RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Alexander Pertsemlidis,et al.  Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9 , 2005, Nature Genetics.

[35]  D. Baltimore,et al.  Physiological functions for brain NF-κB , 2005, Trends in Neurosciences.

[36]  H. Eiberg,et al.  Mosaicism of the CAG repeat sequence in the Huntington disease gene in a pair of monozygotic twins , 2004, American journal of medical genetics. Part A.

[37]  Jonathan C. Cohen,et al.  Multiple Rare Alleles Contribute to Low Plasma Levels of HDL Cholesterol , 2004, Science.

[38]  Jane S. Paulsen,et al.  A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length , 2004, Clinical genetics.

[39]  Karen Marder,et al.  Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[40]  A. Destée,et al.  Mutation analysis and association studies of the ubiquitin carboxy-terminal hydrolase L1 gene in Huntington's disease , 2002, Neuroscience Letters.

[41]  A. Aggarwal,et al.  Structure of NF-κB p50/p65 Heterodimer Bound to the PRDII DNA Element from the Interferon-β Promoter , 2002 .

[42]  Elena Cattaneo,et al.  Loss of normal huntingtin function: new developments in Huntington's disease research , 2001, Trends in Neurosciences.

[43]  Joseph H. Nadeau,et al.  Modifier genes in mice and humans , 2001, Nature Reviews Genetics.

[44]  J. Hodgson,et al.  Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. , 2001, American journal of human genetics.

[45]  M. Ehrlich,et al.  ST14A Cells Have Properties of a Medium-Size Spiny Neuron , 2001, Experimental Neurology.

[46]  R C Elston,et al.  A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus. , 2001, American journal of human genetics.

[47]  O. Riess,et al.  Isolation and characterization of the rat huntingtin promoter. , 1998, The Biochemical journal.

[48]  E. Cattaneo,et al.  Generation and characterization of embryonic striatal conditionally immortalized ST14A cells , 1998, Journal of neuroscience research.

[49]  D. Rubinsztein,et al.  Functional analysis of the Huntington's disease (HD) gene promoter. , 1998, Human molecular genetics.

[50]  G. Ghosh,et al.  Crystal structure of p50/p65 heterodimer of transcription factor NF-κB bound to DNA , 1998, Nature.

[51]  D. Rubinsztein,et al.  Analysis of the 5' upstream sequence of the Huntington's disease (HD) gene shows six new rare alleles which are unrelated to the age at onset of HD. , 1997, Journal of medical genetics.

[52]  M. Hayden,et al.  The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. , 1997, American journal of human genetics.

[53]  G Norbury,et al.  Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[54]  J. Hodgson,et al.  Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype. , 1996, Human molecular genetics.

[55]  B. Aggarwal,et al.  Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[56]  Y. Agid,et al.  Sequence analysis of the CCG polymorphic region adjacent to the CAG triplet repeat of the HD gene in normal and HD chromosomes. , 1995, Journal of medical genetics.

[57]  R. Albin,et al.  Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues , 1993, Nature Genetics.

[58]  S. Folstein,et al.  Huntington's disease gene (IT15) is widely expressed in human and rat tissues , 1993, Neuron.

[59]  M. Hayden,et al.  The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease , 1993, Nature Genetics.

[60]  R. S. Williams,et al.  Morphometric analysis of the prefrontal cortex in Huntington's disease , 1991, Neurology.

[61]  P Corvol,et al.  An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. , 1990, The Journal of clinical investigation.

[62]  E. Oltz,et al.  Preferential cytotoxicity on tumor cells by caffeic acid phenethyl ester isolated from propolis , 1988, Experientia.

[63]  P. Zamore,et al.  Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain. , 2013, Journal of Huntington's disease.

[64]  D. Baltimore,et al.  Physiological functions for brain NF-kappaB. , 2005, Trends in neurosciences.

[65]  Wyeth W. Wasserman,et al.  JASPAR: an open-access database for eukaryotic transcription factor binding profiles , 2004, Nucleic Acids Res..

[66]  A. Aggarwal,et al.  Structure of NF-kappaB p50/p65 heterodimer bound to the PRDII DNA element from the interferon-beta promoter. , 2002, Structure.

[67]  M. Hayden,et al.  A CCG repeat polymorphism adjacent to the CAG repeat in the Huntington disease gene: implications for diagnostic accuracy and predictive testing. , 1994, Human molecular genetics.